This 2023 NCCN Guidelines Insights report synthesizes evidence-based updates for systemic therapy in metastatic breast cancer (Stage IV). The analysis systematically evaluates recent clinical trial data informing treatment stratification by molecular subtypes and biomarker profiles. Key revisions encompass targeted agents, immunotherapy integration, and sequencing strategies for hormone receptor-positive, HER2-positive, and triple-negative disease. These refinements aim to optimize therapeutic efficacy while managing toxicity profiles in advanced disease settings. The guidelines provide critical framework standardization for multidisciplinary care teams navigating complex treatment decisions in metastatic breast cancer management.